Forward integration strategies can generate value for shareholders but carry with them challenges as well as benefits. This panel will discuss the pros and cons of acquiring a small late-stage or marketed product geared toward a similar audience as an existing pipeline product and how to finance the move.



Objectives:

Help biotech executives determine whether their company is a candidate for forward integration.

Provide direct insight from financiers on what attracts them to biopharmaceutical companies that have pursued a forward integration strategy.

Assess the risks and challenges of pursuing a forward integration strategy.